MERCK KGAA |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 166.2 EUR | -0.60% |
|
+7.61% | +15.37% |
| May. 16 | MERCK KGAA : DZ Bank gives a Buy rating | ZD |
| May. 16 | MERCK KGAA : Gets a Buy rating from Barclays | ZD |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 21.25B 23.1B | Sales 2025 * | 22.47B 24.43B | Capitalization | 72.69B 79.02B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.98B 3.24B | Net income 2025 * | 3.48B 3.78B | EV / Sales 2024 * | 3.42 x |
| Net cash position 2024 * | - 0 | Net Debt 2025 * | 4.49K 4.88K | EV / Sales 2025 * | 3.24 x |
| P/E ratio 2024 * |
24.1
x | P/E ratio 2025 * |
20.5
x | Employees | 62,345 |
| Yield 2024 * |
1.36% | Yield 2025 * |
1.45% | Free-Float | 29.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck KGaA
More press releases
More news
| 1 day | +0.27% | ||
| 1 week | +8.41% | ||
| Current month | +12.45% | ||
| 1 month | +13.41% | ||
| 3 months | +9.19% | ||
| 6 months | +4.00% | ||
| Current year | +16.24% |
1 week
155.10
169.05
1 month
146.10169.05
Current year
140.50169.05
1 year
134.30172.40
3 years
134.30231.50
5 years
76.22231.50
10 years
61.05231.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 20-07-12 | |
Marcus Kuhnert
DFI | Director of Finance/CFO | 56 | 14-07-31 |
| Director of Finance/CFO | 53 | 19-04-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 14-05-08 | |
| Chairman | 67 | 19-04-25 | |
Jürgen Glaser
BRD | Director/Board Member | 61 | 12-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.34% | 2 M€ | +13.56% | - | |
| 2.01% | 0 M€ | 0.00% | - | |
| 1.80% | 962 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 166.2 | -0.57% | 25 763 |
| 24-05-17 | 167.2 | -0.89% | 286,898 |
| 24-05-16 | 168.7 | +1.72% | 498,812 |
| 24-05-15 | 165.8 | +4.77% | 741,893 |
| 24-05-14 | 158.3 | +2.46% | 298,795 |
Delayed Quote Xetra, May 20, 2024 at 05:10 am EDT
More quotes
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows:
- solutions and products for scientific and biotechnological research (44.2%);
- pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.;
- performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc.
Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q2 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
167.2
EUR
Average target price
182.3
EUR
Spread / Average Target
+9.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.24% | 79.03B | |
| +10.49% | 8.96B | |
| -10.76% | 5.19B | |
| +51.58% | 4.77B | |
| +12.50% | 4.26B | |
| -20.70% | 2.37B | |
| +12.49% | 2.3B | |
| -29.65% | 2.21B | |
| +19.51% | 2.17B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- MRK Stock
